Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

0.62

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

2

Target Price

5

Analyst Recom

1

Performance Q

3.26

Relative Volume

0.19

Beta

Ticker: IMRN



21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-01-23IMRN2.05N/AN/A0
2025-01-24IMRN2N/AN/A0
2025-01-27IMRN1.95N/AN/A0
2025-01-28IMRN2.06N/AN/A0
2025-01-29IMRN2.01N/AN/A0
2025-01-30IMRN2.16N/AN/A0
2025-01-31IMRN2.08N/AN/A0
2025-02-03IMRN1.98N/AN/A0
2025-02-04IMRN2.1N/AN/A0
2025-02-05IMRN2.04N/AN/A0
2025-02-06IMRN2.01N/AN/A0
2025-02-07IMRN1.96N/AN/A0
2025-02-10IMRN2.05N/AN/A0
2025-02-11IMRN2N/AN/A0
2025-02-12IMRN1.98N/AN/A0
2025-02-13IMRN2.0198N/AN/A0
2025-02-14IMRN2.04N/AN/A0
2025-02-18IMRN2.03N/AN/A0
2025-02-19IMRN1.96N/AN/A0
2025-02-20IMRN1.89N/AN/A0
2025-02-21IMRN1.9N/AN/A0
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1



21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-01-23IMRN2.05- - 0.00
2025-01-24IMRN2.03- - 0.00
2025-01-27IMRN2.00- - 0.00
2025-01-28IMRN2.01- - 0.00
2025-01-29IMRN2.01- - 0.00
2025-01-30IMRN2.16- - 0.00
2025-01-31IMRN2.04- - 0.00
2025-02-03IMRN1.98- - 0.00
2025-02-04IMRN2.10- - 0.00
2025-02-05IMRN2.10- - 0.00
2025-02-06IMRN2.04- - 0.00
2025-02-07IMRN2.01- - 0.00
2025-02-10IMRN2.01- - 0.00
2025-02-11IMRN2.01- - 0.00
2025-02-12IMRN2.00- - 0.00
2025-02-13IMRN2.02- - 0.00
2025-02-14IMRN2.04- - 0.00
2025-02-18IMRN2.03- - 0.00
2025-02-19IMRN1.96- - 0.00
2025-02-20IMRN1.90- - 0.00
2025-02-21IMRN2.00- - 0.00
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1



21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-01-23IMRN0-48.380.28
2025-01-24IMRN0-48.380.28
2025-01-27IMRN0-48.040.28
2025-01-28IMRN0-48.040.77
2025-01-29IMRN0-48.040.77
2025-01-30IMRN0-48.040.77
2025-01-31IMRN0-48.040.77
2025-02-03IMRN0-51.380.77
2025-02-04IMRN0-51.380.77
2025-02-05IMRN0-51.380.77
2025-02-06IMRN0-51.380.77
2025-02-07IMRN0-51.380.77
2025-02-10IMRN0-52.750.77
2025-02-11IMRN0-52.750.77
2025-02-12IMRN0-52.750.62
2025-02-13IMRN0-52.750.62
2025-02-14IMRN0-52.750.62
2025-02-18IMRN0-51.950.62
2025-02-19IMRN0-51.950.62
2025-02-20IMRN0-51.950.62
2025-02-21IMRN0-51.950.62
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

-51.95

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

43

Growth Score

50

Sentiment Score

39

Actual DrawDown %

93.1

Max Drawdown 5-Year %

-92.6

Target Price

5

P/E

Forward P/E

PEG

P/S

3.46

P/B

1.28

P/Free Cash Flow

EPS

-0.8

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-141.71

Relative Volume

0.19

Return on Equity vs Sector %

-73.8

Return on Equity vs Industry %

-58.2

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Immuron Limited
Sector: Healthcare
Industry: Biotechnology
Employees: 7
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops Travelan (IMM-124E), which is in Phase II clinical trial, to reduce the risk of contracting travelers' diarrhea; and IMM-529, which is in Phase II clinical trial, for treating patients suffering from recurring clostridium difficile infection. The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
stock quote shares IMRN – Immuron Limited ADR Stock Price stock today
news today IMRN – Immuron Limited ADR stock forecast ,stock prediction 2023 2024 2025
marketwatch IMRN – Immuron Limited ADR yahoo finance google finance
stock history IMRN – Immuron Limited ADR invest stock market
stock prices IMRN premarket after hours
ticker IMRN fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Facebook-f Twitter Tiktok Instagram Youtube

Get Started

About